ZA201404269B - 2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound as voltage-gated sodium channels modulator - Google Patents
2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound as voltage-gated sodium channels modulatorInfo
- Publication number
- ZA201404269B ZA201404269B ZA2014/04269A ZA201404269A ZA201404269B ZA 201404269 B ZA201404269 B ZA 201404269B ZA 2014/04269 A ZA2014/04269 A ZA 2014/04269A ZA 201404269 A ZA201404269 A ZA 201404269A ZA 201404269 B ZA201404269 B ZA 201404269B
- Authority
- ZA
- South Africa
- Prior art keywords
- diaza
- nonane
- spiro
- pyridin
- compound
- Prior art date
Links
- -1 2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound Chemical class 0.000 title 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 title 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579613P | 2011-12-22 | 2011-12-22 | |
| GBGB1122113.2A GB201122113D0 (en) | 2011-12-22 | 2011-12-22 | Novel compounds |
| PCT/GB2012/053233 WO2013093496A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4] nonane- 6 -one compound as voltage-gated sodium channels modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201404269B true ZA201404269B (en) | 2016-06-29 |
Family
ID=45572877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/04269A ZA201404269B (en) | 2011-12-22 | 2014-06-10 | 2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound as voltage-gated sodium channels modulator |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9303032B2 (OSRAM) |
| EP (2) | EP2797922B1 (OSRAM) |
| JP (2) | JP2015502394A (OSRAM) |
| KR (1) | KR20140113692A (OSRAM) |
| CN (1) | CN104271581B (OSRAM) |
| AU (1) | AU2012356386A1 (OSRAM) |
| BR (1) | BR112014014940A2 (OSRAM) |
| CA (1) | CA2858938C (OSRAM) |
| EA (1) | EA026500B1 (OSRAM) |
| ES (1) | ES2581327T3 (OSRAM) |
| GB (1) | GB201122113D0 (OSRAM) |
| HK (2) | HK1203501A1 (OSRAM) |
| IL (1) | IL233215A0 (OSRAM) |
| IN (1) | IN2014MN01469A (OSRAM) |
| MX (1) | MX2014007637A (OSRAM) |
| SG (1) | SG11201403356YA (OSRAM) |
| WO (2) | WO2013093497A1 (OSRAM) |
| ZA (1) | ZA201404269B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| RU2650523C1 (ru) | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| AU2018347349A1 (en) * | 2017-10-10 | 2020-04-23 | Biogen Inc. | Process for preparing spiro derivatives |
| BR112020009361A2 (pt) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| CN113563258A (zh) * | 2021-07-29 | 2021-10-29 | 派普医药(江苏)有限公司 | 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法 |
| WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
| TW202322794A (zh) * | 2021-09-24 | 2023-06-16 | 加拿大商再諾製藥公司 | 做為鈉通道活化劑之吡啶基衍生物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| WO1996025405A1 (en) | 1995-02-13 | 1996-08-22 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| BR9708574A (pt) | 1996-04-12 | 1999-08-03 | Searle & Co | Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2 |
| EA001444B1 (ru) | 1996-07-18 | 2001-04-23 | Мерк Фросст Кэнада Энд Ко./Мерк Фросст Кэнада Э Си | Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2 |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| DE69827419T2 (de) | 1997-09-05 | 2005-10-27 | Glaxo Group Ltd., Greenford | Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-Pyrazolo[1,5-b]Pyridazin Derivate |
| ES2228127T3 (es) | 1998-11-03 | 2005-04-01 | Glaxo Group Limited | Derivados de pirazolopiridina como inhibidores selectivos de cox-2. |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| ATE261444T1 (de) | 1999-02-27 | 2004-03-15 | Glaxo Group Ltd | Pyrazolopyridine |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| WO2007042250A1 (en) | 2005-10-10 | 2007-04-19 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| TW200728258A (en) * | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| US7505330B2 (en) * | 2006-08-31 | 2009-03-17 | Micron Technology, Inc. | Phase-change random access memory employing read before write for resistance stabilization |
| AU2008208920A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1 |
| GB0701366D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| SI2477964T1 (sl) | 2009-09-14 | 2015-10-30 | Convergence Pharmaceuticals Limited | Postopek za pripravo derivatov alfa-karboksamida |
| US8445696B2 (en) * | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2011
- 2011-12-22 GB GBGB1122113.2A patent/GB201122113D0/en not_active Ceased
-
2012
- 2012-12-21 WO PCT/GB2012/053234 patent/WO2013093497A1/en active Application Filing
- 2012-12-21 EP EP12810416.3A patent/EP2797922B1/en not_active Not-in-force
- 2012-12-21 BR BR112014014940A patent/BR112014014940A2/pt not_active Application Discontinuation
- 2012-12-21 KR KR1020147019965A patent/KR20140113692A/ko not_active Withdrawn
- 2012-12-21 JP JP2014548201A patent/JP2015502394A/ja active Pending
- 2012-12-21 SG SG11201403356YA patent/SG11201403356YA/en unknown
- 2012-12-21 US US14/365,391 patent/US9303032B2/en not_active Expired - Fee Related
- 2012-12-21 MX MX2014007637A patent/MX2014007637A/es unknown
- 2012-12-21 US US14/365,372 patent/US9376436B2/en not_active Expired - Fee Related
- 2012-12-21 IN IN1469MUN2014 patent/IN2014MN01469A/en unknown
- 2012-12-21 CN CN201280070485.0A patent/CN104271581B/zh not_active Expired - Fee Related
- 2012-12-21 EP EP12810417.1A patent/EP2794612B1/en not_active Not-in-force
- 2012-12-21 JP JP2014548202A patent/JP2015502395A/ja active Pending
- 2012-12-21 CA CA2858938A patent/CA2858938C/en active Active
- 2012-12-21 EA EA201491251A patent/EA026500B1/ru unknown
- 2012-12-21 HK HK15104075.3A patent/HK1203501A1/xx unknown
- 2012-12-21 ES ES12810416.3T patent/ES2581327T3/es active Active
- 2012-12-21 WO PCT/GB2012/053233 patent/WO2013093496A1/en active Application Filing
- 2012-12-21 HK HK15103930.0A patent/HK1203492A1/xx unknown
- 2012-12-21 AU AU2012356386A patent/AU2012356386A1/en not_active Abandoned
-
2014
- 2014-06-10 ZA ZA2014/04269A patent/ZA201404269B/en unknown
- 2014-06-18 IL IL233215A patent/IL233215A0/en unknown
-
2016
- 2016-02-25 US US15/053,445 patent/US20160185758A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2858938C (en) | 2020-03-10 |
| KR20140113692A (ko) | 2014-09-24 |
| WO2013093496A1 (en) | 2013-06-27 |
| MX2014007637A (es) | 2014-09-26 |
| GB201122113D0 (en) | 2012-02-01 |
| US20150225400A1 (en) | 2015-08-13 |
| US9303032B2 (en) | 2016-04-05 |
| EA201491251A1 (ru) | 2014-11-28 |
| CA2858938A1 (en) | 2013-06-27 |
| US20160185758A1 (en) | 2016-06-30 |
| IN2014MN01469A (OSRAM) | 2015-04-17 |
| EP2797922A1 (en) | 2014-11-05 |
| BR112014014940A2 (pt) | 2017-06-13 |
| JP2015502394A (ja) | 2015-01-22 |
| EA026500B1 (ru) | 2017-04-28 |
| JP2015502395A (ja) | 2015-01-22 |
| WO2013093497A1 (en) | 2013-06-27 |
| HK1203501A1 (en) | 2015-10-30 |
| IL233215A0 (en) | 2014-08-31 |
| HK1203492A1 (en) | 2015-10-30 |
| SG11201403356YA (en) | 2014-07-30 |
| US20140350040A1 (en) | 2014-11-27 |
| EP2794612B1 (en) | 2016-04-06 |
| ES2581327T3 (es) | 2016-09-05 |
| CN104271581A (zh) | 2015-01-07 |
| AU2012356386A1 (en) | 2014-07-10 |
| CN104271581B (zh) | 2016-08-31 |
| EP2794612A1 (en) | 2014-10-29 |
| US9376436B2 (en) | 2016-06-28 |
| EP2797922B1 (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233215A0 (en) | Compound 2-(pyridine-2-yl)-7,1-diaza-spiro[4.4]nonane-6-one as a modulator of voltage-gated sodium channels | |
| SI3686194T1 (sl) | Spojine 2-(2,4,5-substituiranega-anilino)pirimidina | |
| ZA201206440B (en) | [5,6]heterocyclic compound | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| EP2875029B8 (en) | 5,5-heteroaromatic anti-infective compounds | |
| EP2699091A4 (en) | 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS | |
| AP2010005408A0 (en) | Fused pyrimidineone compounds as TRPV3 modulators. | |
| EP2723741B8 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| SI2384326T1 (sl) | Pirolo(2,3-d)pirimidinske spojine | |
| SI2694508T1 (sl) | Soli substituiranega 2,3-dihidroimidazo(1,2-C)kinazolina | |
| WO2012167171A3 (en) | Z-selective ring-closing metathesis reactions | |
| ZA201205788B (en) | 1,2,4-triazine-4-amine derivatives | |
| EP2624698A4 (en) | Furo [3,2-D] PYRIMIDINE COMPOUNDS | |
| AP2011005706A0 (en) | New compounds. | |
| IL232917A0 (en) | History of 5-(3-aminophenyl)-5-alkyl-6,5-dihydro-2h[4,1]oxazin-3-amine | |
| ZA201404074B (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
| PL2531505T3 (pl) | Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami | |
| ZA201306229B (en) | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines | |
| EP2687520A4 (en) | PROCESS FOR PREPARING A 1,2-BENZISOTHIAZOL-3-ON COMPOUND | |
| EP2883870B8 (en) | Method for producing 1,4-benzoxazine compound | |
| EP2687519A4 (en) | PROCESS FOR PRODUCING 1,2-BENZISOTHIAZOL-3-ONE COMPOUNDS | |
| SI2266990T1 (sl) | Spojina 3-fenilpirazolo(5,1-b)tiazola | |
| IL213762A0 (en) | 1,1,1-trifluoro-2-hydroxypropyl compounds | |
| IL228270A0 (en) | History of 1-h- pyrrolidine -4,2-dione spirocyclics converted in cis-alkoxy | |
| HK40086830A (en) | 2-(2,4,5-substituted-anilino)pyrimidine compounds |